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Abstract
Background:  Coronary Artery Bypass Graft operation for ischemic heart disease provides
improved quality of life and, in some patients, prolonged survival. Concern has, however, been
raised about complications that may be related to the use of cardiopulmonary by-pass (CPB) and
aortic cross-clamping. It has been hypothesized that when coronary artery by-pass grafting is
performed without the use of CPB, the rate of serious complications is reduced.
Methods/Design: The trial is designed as an open, randomized, controlled, clinical trial with
blinded assessment of end-points. Patients at or above 70 years of age, referred for surgical
myocardial revascularisation, are included and randomised to receive coronary artery by-pass
grafting either with or without the use of CPB and aortic cross-clamping. Follow-up is performed
by clinical, biochemical, electrocardiographic, and angiographic data that are evaluated by
independent committees that are blinded with respect to the result of the randomisation. End
points include mortality, stroke, myocardial infarction, graft patency, quality of life, and cost-
effectiveness. The trial is performed in four different Danish, cardiac surgery centres.
Trial registration: ClinicalTrials.gov NCT00123981
Background
Conventional Coronary Artery By-pass Grafting (CCABG)
using CPB has for decades been applied to obtain myocar-
dial re-vascularisation and, hence, improved quality of life
and survival. It does, however, bear a risk of death, stroke,
myocardial infarction and other serious complications.
During recent years, an equivalent operation performed
on the beating heart without cardiopulmonary bypass
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(Off-pump Coronary Artery By-pass Grafting, OPCAB)
has gained popularity helped by the advent of mechanical
stabilization devices and improved surgical techniques.
Observational studies suggest that this technique is asso-
ciated with a lower incidence of stroke, per operative
arrhythmias and even mortality than conventional
CCABG [1]. This is especially the case in elderly patients
and patients with significant co-morbidity [2-4].
Only few randomised, controlled trials have been con-
ducted [5-9] and most of these included mainly or only
low-risk, relatively young patients. These studies have
documented the safety and efficacy of OPCAB compared
with CCABG, but none of the trials has had the statistical
power to determine whether the rate of serious complica-
tions is lower after OPCAB operations. In contrast to ear-
lier findings [5], one recent study found graft patency to
be significantly lower after OPCAB than after CCABG
operations [9].
We find that there is a need of a larger scale randomised
trial to compare the results of CCABG and OPCAB opera-
tions, especially in elderly patients.
Aims
Primarily, to compare the incidence of death, stroke and
myocardial infarction after CCABG and OPCAB proce-
dures in a population of elderly patients. Secondly, to
compare quality of life and graft patency, and cost-effec-
tiveness after CCABG and OPCAB.
Design
An open, randomised Danish multicentre trial of patients
70 years of age or above, admitted for surgical, first time
myocardial re-vascularisation. The design involves
blinded evaluation of outcome measures and interim
analyses.
Participating centres
The study will be performed at the cardiac surgery units of
Aalborg Hospital, Aarhus University Hospital, Gentofte
Hospital, Odense University Hospital, and Aarhus Uni-
versity Hospital, Skejby, Denmark.
Approval to start
Patients will be enrolled in the study based upon written
informed consent in accordance with Helsinki Declara-
tion II. The study plan has been approved by the local eth-
ical committees and the national ethical committee.
Trial surgeon's requirements
Before being certified to participate, the surgeons must at
least independently have performed 25 CCABG and 25
OPCAB procedures each procedure including anastomo-
ses to the marginal tbranches of the left coronary artery.
This territory is the most challenging to graft. Therefore,
all surgeons fulfilling this criterium will first have per-
formed a significant number of other coronary artery by-
pass operations and have an intermediate level of experi-
ence reflecting common clinical situations. Based upon
these criteria and on documented results of the opera-
tions, surgeons must also be certified by the ethical and
safety data committee.
Inclusion criteria
Patients age seventy years or above admitted for first time
coronary artery by-pass operation without other planned
surgical procedure.
Exclusion criteria
- Patient not willing to participate in the study
- The patient cannot understand given information or
answer questionnaires relevantly due to intellectual or lin-
guistic deficiency
- Preoperative knowledge that aortic cross clamping is not
safe due to calcification e.g. from CT-scan.
- Preoperative cardiac conditions demanding CPB.
- Re-do cardiac surgery.
- Acute operation defined as patient requiring operation
before the beginning of the next working day after first
being presented to the surgeon.
- Any other reason why the operating surgeon does not
believe that the patient can be operated safely either using
CPB or without CPB.
- Inclusion in study not possible for logistic reasons
Consent and inclusion procedure
After written and oral information is given by the project
nurse at the ward at time of admission for coronary artery
by-pass grafting, the patient has to give oral and written
consent.
Randomisation
The operating surgeon enters patients in a central data-
base accessed by the internet. Before being able to ran-
domise, the surgeon has to enter a preoperative plan
including which coronary arteries are to be grafted, the
conduit type and whether a single, sequential, or y-graft is
planned. Having done this the patient is subsequently
randomised either to OPCAB or CCABG by the on-line
system
Blinding
For practical end ethical reasons, neither the patient nor
doctors or nurses are blinded with respect to the type ofTrials 2009, 10:47 http://www.trialsjournal.com/content/10/1/47
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treatment used. Events will, however, be evaluated by an
independent committee that will be blinded.
Sample size
900 patients including 450 patients randomised for
OPCAB and 450 randomized for CCABG.
Power calculations
The incidence of the primary, combined end-point is esti-
mated to be 8%. This estimate is based on literature as
well as on historical data from the participating centres
from the period 2001–2003. Based on earlier, observa-
tional studies of elderly patients undergoing coronary
revascularisation [2,3], we hypothesize that this incidence
can be reduced to 4% by avoiding cardiopulmonary by-
pass. With a margin of 0.5% in risk difference a test of
non-inferiority of OPCAB compared to CCABG based on
900 patients will have a statistical power of 82%.
Operations and anaesthesia
The coronary artery by-pass operations are performed
either with or without the use of CPB according to the
result of randomisation. Operative protocols are used to
limit the variations of technique, although leaving some
room for variations according to the discretion of the indi-
vidual surgeon and the tradition of each participating
unit. The operative protocols are given in Appendix 1.
When judged vital for the outcome of the patient, conver-
sion from one group to the other can be decided by the
operating surgeon at any time during the operation.
Equally, anaesthetic protocols are followed in order to
limit the variations between the units (Appendix 2)
Postoperative treatment
Postoperative treatment of included patients with acetyl
salicylic acid, clopidogrel, angiotensin converting enzyme
inhibitors, diuretics, amiodarone and heparin will be per-
formed according to detailed protocols (Appendix 3)
In case deviation from the protocol is deemed necessary,
such altered strategies are to be duly noted and accounted
for.
Follow-up
At preoperative conference: Evaluation of whether the
patient meets the inclusion and/or exclusion criteria. All
patients above 70 years who are to have a sole by-pass
operation are registered. If the patient is not included in
the project, the reason is noted.
Day one: The day the patient is admitted to the hospital for
operation. Informed oral and written information and
consent. Questionnaires are answered.
Day two: Randomization. CCABG or OPCAB are per-
formed according to randomization.
Day 31: Telephone contact and ECG. Evaluation of pri-
mary end-point.
Six months postoperatively: Coronary angiography. Clinical
control and questionnaire.
Three years postoperatively: Clinical control and question-
naire.
During follow-up the patients will be followed up
through unambiguous record linkage with population-
based registries by using the civil registry number, which
is a unique identification code given to every person resid-
ing in Denmark at birth or upon immigration. Informa-
tion on death will be obtained from the Civil Registration
System, which keeps electronic records on all changes in
vital status, including change of address, date of emigra-
tion, and date of death for the entire Danish population.
Information on hospitalizations for myocardial infarction
and stroke will be obtained from The National Registry of
Patients, which retains key information on all patients
discharged from non-psychiatric hospitals in Denmark
since 1977, including outpatient diagnoses, and patients
dying during their admission. The files of the registry
include information on the civil registry number of the
patient, date of discharge, and up to 20 discharge diag-
noses, assigned exclusively by the physician at discharge
according to the Danish version of the International Clas-
sification of Diseases, 10th revision (ICD-10) thereafter
[10]. Full medical records including results of paraclinical
examinations and tests will be retrieved and reviewed
according to standardized internationally accepted criteria
for all patients who die and/or are registered with a dis-
charge diagnosis of acute myocardial infarction or stroke
during the study period. All data will be presented for the
independent monitoring committee.
Primary endpoint
A combined end-point of death + stoke + myocardial inf-
arction within 30 days postoperatively. Definitions of
end-points will be according to appendix 4.
Secondary endpoints
a) A combined end-point of death + stoke + myocar-
dial infarction during follow-up
b) Patency of by-pass grafts assessed by coronary ang-
iography 6 months after the operation.
c) Total mortality and cardiac mortality during follow-
up.
d) Need of new intervention for cardiac angina during
follow-up.Trials 2009, 10:47 http://www.trialsjournal.com/content/10/1/47
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e) Quality of life assessed by MOS SF-36 and EuroQol
questionnaires 6 months and 3 years after the opera-
tion.
f) Total hospital costs and costs of public care pro-
vided 6 months and 3 years after the operation and
difference in costs per quality adjusted life year.
Analysis
Kaplan-Meier plots will be used for graphic comparisons
between groups and log- rank test for numerical compari-
son. Data analysis will be performed in accordance with
the principle of intention-to-treat. An interim analysis will
be performed for monitoring the accumulating data dur-
ing the planned study period, i.e., after half of the patients
have been recruited. The O'Brien-Fleming approach will
be used in these analyses. At the interim analysis a p-value
below 0.5% will be considered significant, while a p value
below 4.8% will be considered significant after conclu-
sion of the study. In this manner, a 5% level of signifi-
cance is sustained. For the 6 months and 3 years data,
Kaplan-Meier plots will be used for graphic comparisons
between groups and log- rank test for numerical compari-
son.
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Appendices
Appendix 1
A Standard off-pump (OPCAB) procedure
1. Full median sternotomy is used in all patients
2. Graft material is harvested and controlled
3. Heparin is given and the Activated Clotting time
(ACT) is controlled. If necessary, additional heparin is
given to achieve an ACT above 400 sec. before arteriot-
omy.
4. Autotransfusion or cellsaver is used to avoid blood
spill.
5. Opening of the pericardium
6. Devices for mobilization and stabilizing the heart
are positioned
7. The vessel is opened
8. An intracoronary shunt is placed and/or CO- blower
may be used. If necessary, a snare can be placed prox-
imally but not distally to the anastomosis
9. The anastomosis is made with prolene 7.0 running
suture
10. The proximal anastomoses are performed either
before or after performing the distal anastomosis with
minimal manipulation of the aorta. Bilateral internal
mammary artery grafts, Y-grafts can be used but also
proximal anastomosis devices and side-clamping are
allowed.
11. Flow in coronary grafts is controlled using transit-
time flow meter and registered. Eventual redo of the
anastomosis is at the surgeon's discretion.
12. Two atrial and two ventricular pace electrodes are
placed.
13. After the procedure, 4 mg of protamin is given and
if necessary additional protamin in order to fully
revert the heparinization to ACT level below 120 s.
14. Drainage tubes are placed.
i) Sternum is closed with wires and fascia, subcutis
and skin closed with sutures.
B Standard CCABG procedure
1. Full median sternotomy is used in all patients
2. Graft material is harvested and controlled
3. Heparin is given and the Activated Clotting time
(ACT) is controlled. If necessary, additional heparin is
given to achieve an ACT above 400 sec. before arteriot-
omy.
4. The pericardium is opened and pericardial sutures
are placed to expose the heart.
5. Cannulation of right atrium and aorta. Start of car-
diopulmonary by-pass.
6. When the heart is fully relieve, the places where to
place the anastomoses is marked.
7. Cross-clamping of the aorta
8. Cold antegrade or retrograde cardioplegic solution
is given. Both crystalloid and hemocardioplegia are
acceptedTrials 2009, 10:47 http://www.trialsjournal.com/content/10/1/47
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9. Graft material is prepared for anastomosis when
asystoli has occurred and the ordered amount of cardi-
oplegic solution is given, distal anastomoses are made
using 7.0. prolene running suture.
10. Patency and tightness of the anastomosis are tested
using cardioplegic solution if distal anastomoses are
performed before proximal anastomoses.
11. The proximal anastomoses are performed either
before or after performing the distal anastomosis.
Bilateral internal mammary artery grafts, Y-grafts can
be used but also proximal anastomosis devices and
side-clamping are allowed.
12. Flow in coronary grafts is controlled using MediS-
tim Transit-time flow meter and registered. Eventual
redo of the anastomosis is at the surgeon's discretion.
13. Extra-corporeal circulation is gradually decreased
and stopped. Test-dose of protamin is given.
14. Decannulation.
15. After the procedure, protamin is given to fully
revert the heparinization to ACT level below 120 s.
16. Two atrial and two ventricular pace electrodes are
placed.
17. Drainage tubes are placed.
18. Sternum is closed with wires and fascia, subcutis
and skin closed with sutures.
Appendix 2. Anaesthesia
The aim is that all patients receive a standard anesthesia
and perioperative treatment, to minimize the influence of
anesthesia and perioperative care in the included patients.
The following is recommendated guidelines. There will be
slight differences between the involved hospitals, but it is
mandatory for each hospital to secure, that there will be
no differences is anesthesia and perioperative care
between the two groups (OPCAB and CCABG).
Premedication
Peroral midazolam 3.75–7.5 mg one hour prior to sur-
gery. If the patient receives treatment with beta-blocker,
the usual dose is given at the same time.
Anesthesia
Intravenous induction with midazolam (0.05–0.15 mg/
kg) and fentanyl (5–15 μg/kg); muscle relaxation with
rocuronium (0.6 mg/kg). Anesthesia shall be maintained
with either inhalation of sevoflurane or desflurane to
improve ischemic preconditioning and with additional
boluses of fentanyl (total dose, 20–30 μg/kg) and rocuro-
nium. During cardiopulmonary bypass (CPB) the inhala-
tion agent is given to the bypass circuit (Aarhus University
Hospital, Aalborg and Odense University Hospital), alter-
natively an infusion of propofol is given to the bypass cir-
cuit (Aarhus University Hospital, Skejby and Gentofte
Hospital). Aarhus University Hospital, Skejby will use
total intravenous anesthesia due to lack of equipment for
inhalation agent.
Monitoring
Arterial catheter; central venous catheter; pulmonary
artery catheter for measuring of central venous pressure,
pulmonary artery pressure and cardiac output, preferable
a fiberoptic catheter shall be inserted for measuring of
mixed venous saturation (SVO2), 5-lead ECG for measur-
ing of heart rate and cardiac ischemia, peripheral oxygen
saturation (SpO2), end-tidal carbon dioxide (CO2); Mini-
mal alveolar concentration (MAC) of anesthetic inhala-
tion agent; central body temperature (bladder); peripheral
temperature; catheter in the bladder.
All parameters will be recorded continuously according to
the flow chart in each department. Specific defined
parameters will be recorded in the flow chart following
the present study.
Temperature
Normothermia is defined as a central body temperature
(bladder) of 35–37°C.
CABG group: The central body temperature shall be
achieved by a heat-exchanger in the cardiopulmonary
bypass circuit.
OPCAB group: The central body temperature shall be
achieved by using warm intravenous fluids, a heating mat-
tress, a warming blanket, in addition to maintaining a
warm operation theatre.
Ventilation
Mandatory ventilation tidal volume 8–10 ml/kg and the
rate adapted for a partial arterial pressure of CO2 (PaCO2)
between 4.5 and 5.5 kPa, positive end-expiratory pressure
(PEEP) at 5 cmH2O, and FiO2 at 0.4–0.6 to keep partial
arterial pressure of oxygen (PaO2) above10 kPa. Patients
with preoperative chronic obstructive lung disease shall at
least be treated in accordance to their preoperative values
of PCO2 and PO2.
Before closure of sternum, the lungs shall be inflated man-
ually to reopen atelectasis due to pulmonary collapse dur-
ing surgery.Trials 2009, 10:47 http://www.trialsjournal.com/content/10/1/47
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Extubation as soon as the drainage loss in acceptable; the
central body temperature is >36°C and peripheral tem-
perature is >32°C; the circulation is stabilized with a
mean arterial pressure > 70 mmHg, a cardiac index > 2.2
liters/minut/m2 and a heart rate < 90/minute, and if meas-
ured a SvO2>60%; normocapnia and oxygenationindex
(PaO2/FiO2) > 35.
After extubation in intensive care unit (ICU) the aim is a
PO2>10 kPa achieved by supplementary treatment with
either dry oxygen 1–5 litres/minute or humidified oxygen
15 litres/minute with FiO2 between 0.40 and 1.0.
Vasoactive drugs
Vasodilators: Nitroglycerine, nitroprusside, nifidipine.
Vasocontractors: Noradrenaline.
Inotropic agents: Epinephrine, dobutamine, dopamine,
phosphodiesterase inhibitors, calcium sensitizer.
The vasoactive drugs are given on indication to secure
optimal central and peripheral circulation. The drug of
choice depends of the routine in the cardiac units.
Mechanical support
Intraaortic ballon pump and assist device is placed on
indication depending on the routine in the cardiac units.
Volume substitution
Crystalloids: Isotonic saline, isotonic ringers acetate, isot-
onic potassium-glucose.
Colloids: Hydroxyethyl starch, dextran.
Blood products: On indication according to the recom-
mendations on the centres.
Fluids are given to maintain normovolemia and hemat-
ocrite > 0.24.
Blood glucose
All patients, non-insulin dependent and insulin depend-
ent diabetes as well as patients without diabetes shall have
blood glucose monitored carefully during surgery and in
ICU.
The goal of blood glucose level shall be:
Peroperative blood glucose: 6 – 10 mmol/l
Postoperative (ICU) blood glucose: 5 – 7 mmol/l
The maintenance of blood glucose level shall be achieved
by infusion of glucose-insulin-potassium according to the
regime in each hospital.
Postoperative sedation
Infusion of propofol 0.5–2 mg/kg/hour and incremental
dosis of morphine 1–4 mg. Supplementary NSAID is
given according to the regimes in the cardiac units.
Antiemetics
Bolus dose of metoclopramid or ondansetron on indica-
tion.
Appendix 3. Postoperative treatment
Low molecular heparin: Fragmin 5000 IE × 1 untill 7th
postoperative day or discharge from hospital
Acetyl-salicylic-acid: 75 mg × 1
Clopidogrel (Plavix)
75 mg × 1 for three months. Patients who have started
clopidogrel treatment because of earlier implanted stent
or because of acute myocardial infarction will continue
the planned treatment. These patients shall also receive
clopidogrel for at least 3 months postoperatively.
Statines
All patients shall receive treatment with statins. Thyroid
and liver biochemical analyses are controlled before
beginning treatment. In case of planned operations, treat-
ment is paused at the day of admission to hospital but is
started again before discharge
Acute operations
treatment is paused at the day of the operation but is
started again before discharge.
Dose
Pravachol 40 mg × 1, Zocor 20–40 mg × 1, Simvastatin 40
mg × 1 or Zarator 10 mg × 1.
ACE-inhibitors
Shall be used in patients with left ventricular ejection frac-
tion < 50%, congestive heart failure and/or arterial hyper-
tension.
Betablockers
In patients with acute myocardial infarction within the
last year and/or congestive heart failure.
Diuretics and potassium
Congestive heart failure with fluid retention and in some
patients with arterial hypertension.
Amiodarone
In patients clinically affected by postoperative atrial fibril-
lation, initially a bolus of 300 mg is injected intravenously
within 20 minutes, followed by infusion of 1200 mg the
following 24 hours or untill conversion to sinus rhythm.Trials 2009, 10:47 http://www.trialsjournal.com/content/10/1/47
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Infusion through central venous catheter. Bolus injection
can, however be performed through peripheral vein.
Subsequently, oral treatment is T. Cordarone 600 mg × 2
for one week, 400 mg × 2 second week, 200 mg × 2 third
week and 200 mg × 1 during the fourth week followed by
discontiuation of therapy in case of stable sinus rhythm.
Appendix 4. Definitions
A. Postoperative acute myocardial infarction
1. Postoperative acute myocardial infarction: A peak crea-
tine kinase-MB(CK-MB) of at least 75 ng/ml by day 3
2. New Q-wave evidence of MI, along with CK-MB of at
least 50 ng/ml by day 3
3. New Q-wave evidence of MI by day 30 that was not
present at day 3
4. MI (Q-wave or non-Q-wave) as defined by the World
Health Organisation
B. Stroke
The World Health Organization's definition of stroke is
used, i.e., an acute disturbance of focal or global cerebral
function with symptoms lasting more than 24 hr or lead-
ing to death of presumed vascular origin.
Patients with the following ICD-10 discharge diagnosis
codes in the Danish National Patient Registry are consid-
ered possible cases of stroke:
I 61 Intracerebral haemorrhage
I 63 Ischaemic stroke
I 64 Non-specified stroke
Patients with subdural haematoma, epidural bleeding,
retina infarction or infarction caused by subarachnoidal
bleeding, trauma, infection, surgery (not related to CABG
or OPCAB surgery) or a intracerebral tumor are not classi-
fied as stroke patients. Moreover the definition does not
include patients with only non-specific symptom, e.g. iso-
lated dizziness or headache or asymptomatic patients
with infarctions identified only by brain imaging.
Diagnostic work-up: In case of clinical symptoms of
stroke or transient cerebral ischemia (TCI), symptoms
should be noted in the patient file and the neurologist on
duty should be asked to make a formal examination of the
patient. All possible cases of stroke or TCI should undergo
a brain imaging procedure, preferably a MR-diffusion
scan. Should a MR-diffusion scan not be possible, efforts
should be made for the patient to have a CT scan 3–7 days
after the start of symptoms (even if a CT scan has been
made in the acute phase).
C. Graft patency
The coronary angiogram is evaluated by two different car-
diologists. The grafts are rated A: Open, B: Stenotic (more
than 50%), O: Occluded, each for the 1) distal anastomo-
sis, 2) proximal anastomosis og 3) length of the graft. Dis-
crepancies are settled by conference.
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